LORBRENA (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive…
Pfizer Inc. announced that the Phase 3 CROWN study of LORBRENA (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung…
Read More...
Read More...